BIIB(Biogen Inc.) 的财务报表:医疗保健,综合制药。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-12-31 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $10.98B | $10.17B | $9.84B | $9.68B | $9.89B |
| 毛利润 | $8.87B | $7.90B | $7.30B | $7.37B | $7.49B |
| 营业利润 | $2.84B | — | — | — | — |
| 净利润 | $1.56B | $3.05B | $1.16B | $1.63B | $1.29B |
| 经营现金流 | $3.64B | $1.38B | $1.55B | $2.88B | $2.20B |
| 自由现金流 | $3.38B | $1.14B | $1.27B | $2.72B | $2.05B |
| 摊薄每股收益 | $10.40 | $20.87 | $7.97 | $11.18 | $8.79 |